Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
Highlights from ICML 2017: The CLL2-BAG study
Immunotherapy highlights from ICML 2017
Denosumab: the next big drug in myeloma?
BCL2 inhibition and CLL: the role of venetoclax